Dr. Vibha Jawa, Executive Director, Nonclinical Disposition and Bioanalysis at BMS

Axel Ducret, a Roche Senior Principal Scientist, takes us through his work on one of the most important cellular mechanisms in immunotherapy.

CAR T, the rockstar therapy of immuno-oncology, finds its next big challenge in translating research for use in solid tumours.

Single-cell, real-time analysis of oncolytic viruses’ efficacy, and replication in living cancer cells.

Ian A Wilson of ImaginAb delivers the presentation ‘The Value of In Vivo Imaging on the Clinical Development of IO Drugs’ at Oxford Global’s discussion group.

Oxford Global’s Immuno Week showcased new ways of reprogramming the immune system to treat malignancy with TCR-T.

An interview with Rajika Perera, Chief Executive Officer, Poseidon Laboratory

Improving preclinical modelling to translate drugs to the clinic is one of the key priorities in immunotherapy and immuno-oncology today. We sat down with senior representatives from GemPharmatech and MiNA Therapeutics to find out how best to develop the next generation of preclinical modelling.

The tumor microenvironment (TME) supports the development of pro-tumoral macrophages.

T cells can develop an exhausted phenotype as a result of prolonged antigen stimulation.